A Phase 3 interventional study of Ruxolitinib and Placebo in Pancreatic Cancer, sponsored by Incyte Corporation. Terminated at 230 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-26.
Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Pancreatic Neoplasms by Incyte Corporation — 1 open to participants now, 2 under way, 1 of them phase 3. Pancreatic Neoplasms · Incyte Corporation.
Among the 10 studies in Pancreatic Neoplasms by Incyte Corporation, this one is the 2nd largest by enrollment, is one of 2 that started in 2014, is one of 3 in phase 3, and was the 5th registered.
3,904 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.
Browse Pancreatic Neoplasms studies →1 of the 10 studies in Pancreatic Neoplasms by Incyte Corporation is open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Australia, Austria and 19 more countries
Ages 18+
By country, each count listing its studies:
Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 3
First in 2011; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 321 is above the median of 47 across 2,935 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 111 across the 10 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
1 of the studies in Pancreatic Neoplasms by Incyte Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02955940Incyte CorporationAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Pancreatic Neoplasms by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Determining the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of advanced or metastatic pancreatic cancer.
This was a randomized, double-blinded, placebo-controlled, Phase 3 study, in which approximately 310 participants with advanced or metastatic adenocarcinoma of the pancreas who have failed, or were intolerant to first-line chemotherapy, were to be randomized (1:1) to one of the following treatment groups:
Treatment consisted of repeating 21-day cycles. Capecitabine was self-administered for the first 14 days of each cycle, and ruxolitinib/placebo was self-administered daily for each cycle. Treatment for all participants continued as long as the regimen was tolerated, and the participant did not meet discontinuation criteria. Participants who discontinued study treatment before study termination were monitored for safety up to 30-35 days from the end of treatment. All participants were followed for survival until study termination or the safety follow-up visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ruxolitinib · Drug: Capecitabine
Drug: Placebo · Drug: Capecitabine
5 mg tablets to be administered by mouth twice daily (BID)
Also known as: Jakafi ®, Jakavi ®
5 mg tablets to be administered by mouth twice daily (BID)
150 and 500 mg tablets to be administered by mouth twice daily (BID)
Overall Survival (OS)
Overall survival is reported here based on the number of deaths from randomization up to 6-months or to the data cutoff 11FEB2016.
Time frame: Randomization until death due to any cause; up to the data cutoff 11FEB2016.
Progression-free Survival (PFS)
Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.
Time frame: Randomization to disease progression, or death due to any cause if sooner; up to 6-months or to the data cutoff 11FEB2016.
Percentage of Participants Achieving Progression Free Survival (PFS)
PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause if sooner. Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.
Time frame: Randomization to disease progression, or death due to any cause if sooner; up to 6-months or to the data cutoff 11FEB2016.
Objective Response Rate (ORR)
Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.
Time frame: Baseline through end of study; up to 6-months or to the data cutoff 11FEB2016.
Duration of Response
Duration of overall response was defined as the time in months from Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) until the first date Progressive Disease (PD) was objectively documented or until the date of death.
Time frame: Baseline through end of study; up to 6-months or to the data cutoff 11FEB2016.
Participants With Treatment-Emergent Adverse Events (TEAEs)
A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug (ruxolitinib or placebo). A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).
Time frame: Baseline through approximately 30 days post treatment discontinuation; up to 6-months or to the data cutoff 11FEB2016.
Participants with advanced or metastatic adenocarcinoma of the pancreas who had failed or were intolerant to first-line chemotherapy were randomized in the study.
| Milestone | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine |
|---|---|---|
| Started | 161 | 160 |
| Completed | 5 | 4 |
| Not completed | 156 | 156 |
| Withdrew: Death | 13 | 8 |
| Withdrew: Adverse event | 8 | 16 |
| Withdrew: Subject decision | 8 | 9 |
| Withdrew: Disease progression | 104 | 108 |
| Withdrew: Noncompliance with study treatment | 1 | 0 |
| Withdrew: Study terminated by the sponsor | 4 | 6 |
| Withdrew: Physician decision | 7 | 2 |
| Withdrew: Other unspecified | 11 | 7 |
Overall survival is reported here based on the number of deaths from randomization up to 6-months or to the data cutoff 11FEB2016.
| Participants | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine |
|---|---|---|
| Observed | 113 | 124 |
| Censored | 48 | 36 |
Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.
| days | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine |
|---|---|---|
| Progression-free Survival (PFS) | 43.0 (41.0 to 46.0) | 44.0 (42.0 to 48.0) |
PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause if sooner. Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.
| percentage of participants | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine |
|---|---|---|
| Survival rate at 3 months | 18.9 (12.7 to 25.9) | 19.8 (13.6 to 26.8) |
| Survival rate at 6 months | 6.1 (2.5 to 12.2) | 5.7 (2.3 to 11.3) |
| Survival rate at 9 months | 2.5 (0.5 to 7.5) | 3.4 (1.0 to 8.5) |
| Survival rate at 12 months | 2.5 (0.5 to 7.5) | NA (NA to NA) |
Objective response rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment and was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST) at any post baseline visit. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) for target lesions and assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI) : Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions with no worsening of non-target lesions and no new lesions; Overall Response (OR) = CR + PR.
| percentage of participants | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine |
|---|---|---|
| Objective response | 3.7 | 1.9 |
| Complete response | 0 | 0 |
| Partial response | 3.7 | 1.9 |
Duration of overall response was defined as the time in months from Complete Response (CR) or Partial Response (PR) by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) until the first date Progressive Disease (PD) was objectively documented or until the date of death.
| days | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine |
|---|---|---|
| Duration of Response | NA (NA to NA) | NA (NA to NA) |
A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug (ruxolitinib or placebo). A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).
| Participants | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine |
|---|---|---|
| Participants who had any TEAEs | 152 | 152 |
| Participants who had treatment-related TEAEs | 73 | 59 |
| Participants who had SAEs | 94 | 83 |
| Participants who had Grade 3 or higher TEAEs | 112 | 113 |
| Participants hospitalized because of a TEAE | 89 | 75 |
| Participants discontinued treatment due to TEAE | 12 | 22 |
| Participants with a dose modification due to TEAE | 68 | 48 |
| Participants on concomitant medication due to TEAE | 131 | 122 |
| Participants with procedure performed due to TEAE | 60 | 46 |
| Participants who had a fatal TEAE | 20 | 15 |
Collected over From the first dose of study medication through study termination up to 6-months or to the data cutoff 11Feb2016.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib Plus Capecitabine | — | 94/153 (61.4%) | 147/153 (96.1%) |
| Placebo Plus Capecitabine | — | 83/154 (53.9%) | 145/154 (94.2%) |
| Event | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine |
|---|---|---|
| Abdominal painGastrointestinal disorders | 6/153 | 19/154 |
| PyrexiaGeneral disorders | 8/153 | 1/154 |
| VomitingGastrointestinal disorders | 7/153 | 4/154 |
| DehydrationMetabolism and nutrition disorders | 7/153 | 4/154 |
| PneumoniaInfections and infestations | 4/153 | 7/154 |
| AscitesGastrointestinal disorders | 5/153 | 1/154 |
| DiarrhoeaGastrointestinal disorders | 5/153 | 4/154 |
| SepsisInfections and infestations | 5/153 | 5/154 |
| HyponatraemiaMetabolism and nutrition disorders | 5/153 | 1/154 |
| Renal failure acuteRenal and urinary disorders | 5/153 | 1/154 |
| Event | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine |
|---|---|---|
| FatigueGeneral disorders | 47/153 | 50/154 |
| NauseaGastrointestinal disorders | 45/153 | 49/154 |
| Abdominal painGastrointestinal disorders | 36/153 | 49/154 |
| Decreased appetiteMetabolism and nutrition disorders | 30/153 | 47/154 |
| VomitingGastrointestinal disorders | 30/153 | 46/154 |
| AnemiaBlood and lymphatic system disorders | 45/153 | 22/154 |
| DiarrheaGastrointestinal disorders | 42/153 | 36/154 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 37/153 | 26/154 |
| Oedema peripheralGeneral disorders | 18/153 | 35/154 |
| ConstipationGastrointestinal disorders | 33/153 | 27/154 |
The intent-to-treat (ITT) population consisted of all participants randomized to the study.
| Age, Continuous(years) | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine | Total |
|---|---|---|---|
| Mean | 67.3 ± 9.35 | 65.6 ± 9.55 | 66.4 ± 9.48 |
| Age, Customized(participants) | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine | Total |
|---|---|---|---|
| ≤ 65 years | 65 | 68 | 133 |
| > 65 years | 96 | 92 | 188 |
| Sex: Female, Male(Participants) | Ruxolitinib Plus Capecitabine | Placebo Plus Capecitabine | Total |
|---|---|---|---|
| Female | 66 | 64 | 130 |
| Male | 95 | 96 | 191 |
Showing the first 100 of 230 sites across 12 countries. Choose a country and city above to see the rest.
Ran from Mar 2014 to primary completion in Feb 2016, 23 months.
Results were first posted in Jul 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib